BioAtla (NASDAQ:BCAB) Downgraded by HC Wainwright to Neutral

HC Wainwright cut shares of BioAtla (NASDAQ:BCAB) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports.

Separately, JMP Securities restated a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Price Performance

Shares of BCAB opened at $1.99 on Wednesday. The stock has a market cap of $96.20 million, a price-to-earnings ratio of -1.17 and a beta of 1.03. The company has a 50-day moving average of $1.92 and a two-hundred day moving average of $1.88. BioAtla has a one year low of $1.14 and a one year high of $4.02.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The company had revenue of $11.00 million for the quarter. During the same quarter last year, the company posted ($0.70) earnings per share. Analysts anticipate that BioAtla will post -1.52 earnings per share for the current year.

Hedge Funds Weigh In On BioAtla

Institutional investors and hedge funds have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA lifted its stake in BioAtla by 5.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after purchasing an additional 28,133 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of BioAtla in the 3rd quarter valued at about $623,000. Chicago Partners Investment Group LLC acquired a new position in BioAtla during the 3rd quarter valued at about $44,000. Vontobel Holding Ltd. acquired a new position in BioAtla during the 3rd quarter valued at about $28,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioAtla during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.